Atlas Trials

Relay Therapeutics, Inc.

5 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Relay Therapeutics, Inc.

RecordFirmDate
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors (NCT07584226)Relay Therapeutics, Inc.2026-03-09
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer (NCT06982521)Relay Therapeutics, Inc.2025-08-26
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) (NCT06789913)Relay Therapeutics, Inc.2025-06-13
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer (NCT05216432)Relay Therapeutics, Inc.2021-12-08

Track Relay Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.